10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
Portfolio Pulse from Benzinga Newsdesk
10x Genomics' platforms were used in a study featured in Cancer Cell, highlighting a mechanism of glioblastoma recurrence and a potential therapeutic approach. The study showed that inhibiting CSF-1R and fibrotic scar formation improved survival in mice.
September 10, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics' platforms were integral to a study on glioblastoma, featured in Cancer Cell, which identified a recurrence mechanism and potential therapy. This exposure could enhance TXG's reputation and demand for its technologies.
The use of 10x Genomics' platforms in a high-profile study published in Cancer Cell could boost the company's reputation and increase demand for its technologies. The study's findings on glioblastoma recurrence and potential therapies may attract attention from the scientific and medical communities, potentially leading to increased sales and partnerships.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90